| __timestamp | Axsome Therapeutics, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 6620800000 |
| Thursday, January 1, 2015 | 2419289 | 6533000000 |
| Friday, January 1, 2016 | 6343648 | 6452000000 |
| Sunday, January 1, 2017 | 7206691 | 6588100000 |
| Monday, January 1, 2018 | 9351522 | 5975100000 |
| Tuesday, January 1, 2019 | 13598030 | 6213800000 |
| Wednesday, January 1, 2020 | 28896749 | 6121200000 |
| Friday, January 1, 2021 | 66646205 | 6431600000 |
| Saturday, January 1, 2022 | 159253661 | 6440400000 |
| Sunday, January 1, 2023 | 323123000 | 6941200000 |
| Monday, January 1, 2024 | 411359000 | 8593800000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, operational efficiency is key to success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of two prominent players: Eli Lilly and Company and Axsome Therapeutics, Inc., from 2014 to 2023. Eli Lilly, a century-old giant, consistently reported SG&A expenses around $6.5 billion annually, reflecting its expansive global operations. In contrast, Axsome Therapeutics, a relatively new entrant, saw its SG&A expenses skyrocket by over 23,000% from 2014 to 2023, highlighting its aggressive growth strategy. By 2023, Axsome's expenses reached approximately 5% of Eli Lilly's, a significant leap from less than 0.1% in 2014. This stark contrast underscores the different stages and strategies of these companies, offering insights into their operational priorities and market positioning.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and PTC Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Zoetis Inc. vs Axsome Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Novavax, Inc.